Continual reassessment method with multiple toxicity constraints.

نویسندگان

  • Shing M Lee
  • Bin Cheng
  • Ying Kuen Cheung
چکیده

This paper addresses the dose-finding problem in cancer trials in which we are concerned with the gradation of severe toxicities that are considered dose limiting. In order to differentiate the tolerance for different toxicity types and grades, we propose a novel extension of the continual reassessment method that explicitly accounts for multiple toxicity constraints. We apply the proposed methods to redesign a bortezomib trial in lymphoma patients and compare their performance with that of the existing methods. Based on simulations, our proposed methods achieve comparable accuracy in identifying the maximum tolerated dose but have better control of the erroneous allocation and recommendation of an overdose.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Robust EM Continual Reassessment Method in Oncology Dose Finding.

The continual reassessment method (CRM) is a commonly used dose-finding design for phase I clinical trials. Practical applications of this method have been restricted by two limitations: (1) the requirement that the toxicity outcome needs to be observed shortly after the initiation of the treatment; and (2) the potential sensitivity to the prespecified toxicity probability at each dose. To over...

متن کامل

Bayesian Model Averaging Continual Reassessment Method BMA-CRM

This document provides the statistical background for the Bayesian model averaging continual reassessment method (BMA-CRM). The BMA-CRM is a Bayesian model-based phase I clinical trial design. The primary goal of the BMA-CRM is to identify the maximum tolerated dose (MTD) of a new drug, which is typically defined as the dose with a doselimiting toxicity (DLT) probability that is closest to the ...

متن کامل

A simple technique to evaluate model sensitivity in the continual reassessment method.

The continual reassessment method (CRM) is a sequential design used in phase I cancer trials to determine the maximal dose with acceptable toxicity. It has been established that the CRM is consistent under model misspecification but not generally. When the method does not converge to the target percentile, some dose-response models will be more sensitive than others in terms of how close the co...

متن کامل

A trivariate continual reassessment method for phase I/II trials of toxicity, efficacy, and surrogate efficacy.

Recently, many Bayesian methods have been developed for dose finding when simultaneously modeling both toxicity and efficacy outcomes in a blended phase I/II fashion. A further challenge arises when all the true efficacy data cannot be obtained quickly after the treatment so that surrogate markers are instead used (e.g., in cancer trials). We propose a framework to jointly model the probabiliti...

متن کامل

The continual reassessment method and its applications: a Bayesian methodology for phase I cancer clinical trials.

We discuss the continual reassessment method (CRM) and its extension with practical applications in phase I and I/II cancer clinical trials. The CRM has been proposed as an alternative design of a traditional cohort design and its essential features are the sequential (continual) selection of a dose level for the next patients based on the dose-toxicity relationship and the updating of the rela...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:
  • Biostatistics

دوره 12 2  شماره 

صفحات  -

تاریخ انتشار 2011